Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H14N2O2
CAS Number:
Molecular Weight:
218.25
UNSPSC Code:
12161501
PubChem Substance ID:
EC Number:
200-012-8
MDL number:
Form:
crystals
Quality level:
InChI key
GMHKMTDVRCWUDX-UHFFFAOYSA-N
InChI
1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)
SMILES string
CCC1(NC(=O)N(C)C1=O)c2ccccc2
form
crystals
color
off-white
mp
115-118 °C, 135-137 °C
solubility
DMSO: soluble
storage temp.
2-8°C
Quality Level
Gene Information
Looking for similar products? Visit Product Comparison Guide
Biochem/physiol Actions
CYP2B6 and CYP2C19 substrate; anticonvulsive, antiepileptic.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
Preparation Note
(±)-Mephenytoin is soluble in DMSO.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Doaa A Elsherbiny et al.
Journal of pharmacokinetics and pharmacodynamics, 35(2), 203-217 (2008-03-20)
The study aim was to assess the inductive properties of artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and CYP2C19 enzymatic activity. The population pharmacokinetics of S-mephenytoin and its metabolites S-nirvanol and S-4'-hydroxymephenytoin, including enzyme turn-over models for induction
Annalise Di Marco et al.
Drug metabolism and disposition: the biological fate of chemicals, 35(10), 1737-1743 (2007-06-30)
A rapid and sensitive radiometric assay for assessing the potential of drugs to inhibit cytochrome P450 (P450) 2C19 in human liver microsomes is described. The new assay, which does not require high-performance liquid chromatography (HPLC) separation or mass spectrometric detection
Robert S Foti et al.
Drug metabolism and disposition: the biological fate of chemicals, 36(3), 523-528 (2007-12-01)
Understanding the potential for cytochrome P450 (P450)-mediated drug-drug interactions is a critical part of the drug discovery process. Factors such as nonspecific binding, atypical kinetics, poor effector solubility, and varying ratios of accessory proteins may alter the kinetic behavior of
Robert S Foti et al.
Journal of medicinal chemistry, 55(3), 1205-1214 (2012-01-14)
A series of omeprazole-based analogues was synthesized and assessed for inhibitory activity against CYP2C19. The data was used to build a CYP2C19 inhibition pharmacophore model for the series. The model was employed to design additional analogues with inhibitory potency against
Michael Zientek et al.
Journal of pharmacological and toxicological methods, 58(3), 206-214 (2008-07-19)
Inhibition of cytochrome P450 (CYP) is a principal mechanism for metabolism-based drug-drug interactions (DDIs). This article describes a robust, high-throughput CYP-mediated DDI assay using a cocktail of 5 clinically relevant probe substrates with quantification by liquid chromatography/tandem mass spectrometry (LC/MS-MS).
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service